COVID-19 Disease Severity among People with HIV Infection or Solid Organ Transplant in the United States: A Nationally-representative, Multicenter, Observational Cohort Study

Sun, Jing; Patel, Rena C.; Zheng, Qulu; Madhira, Vithal; Olex, Amy L.; Islam, Jessica Y.; French, Evan; Chiang, Teresa Po-Yu; Akselrod, Hana; Moffitt, Richard; Alexander, G. Caleb; Andersen, Kathleen M.; Vinson, Amanda J.; Brown, Todd T.; Chute, Christopher G.; Crandall, Keith A.; Franceschini, Nora; Mannon, Roslyn B.; Kirk, Gregory D.

BACKGROUND: Individuals with immune dysfunction, including people with HIV (PWH) or solid organ transplant recipients (SOT), might have worse outcomes from COVID-19. We compared odds of COVID-19 outcomes between patients with and without immune dysfunction. METHODS: We evaluated data from the National COVID-19 Cohort Collaborative (N3C), a multicenter retrospective cohort of electronic medical record (EMR) data from across the United States, on. 1,446,913 adult patients with laboratory-confirmed SARS-CoV-2 infection. HIV, SOT, comorbidity, and HIV markers were identified from EMR data prior to SARS-CoV-2 infection. COVID-19 disease severity within 45 days of SARS-CoV-2 infection was classified into 5 categories: asymptomatic/mild disease with outpatient care; mild disease with emergency department (ED) visit; moderate disease requiring hospitalization; severe disease requiring ventilation or extracorporeal membrane oxygenation (ECMO); and death. We used multivariable, multinomial logistic regression models to compare odds of COVID-19 outcomes between patients with and without immune dysfunction. FINDINGS: Compared to patients without immune dysfunction, PWH and SOT had a greater likelihood of having ED visits (adjusted odds ratio [aOR]: 1.28, 95% confidence interval [CI] 1.27–1.29; aOR: 2.61, CI: 2.58–2.65, respectively), requiring ventilation or ECMO (aOR: 1.43, CI: 1.43–1.43; aOR: 4.82, CI: 4.78–4.86, respectively), and death (aOR: 1.20, CI: 1.19–1.20; aOR: 3.38, CI: 3.35–3.41, respectively). Associations were independent of sociodemographic and comorbidity burden. Compared to PWH with CD4>500 cells/mm(3), PWH with CD4<350 cells/mm(3) were independently at 4.4-, 5.4-, and 7.6-times higher odds for hospitalization, requiring ventilation, and death, respectively. Increased COVID-19 severity was associated with higher levels of HIV viremia. INTERPRETATION: Individuals with immune dysfunction have greater risk for severe COVID-19 outcomes. More advanced HIV disease (greater immunosuppression and HIV viremia) was associated with higher odds of severe COVID-19 outcomes. Appropriate prevention and treatment strategies should be investigated to reduce the higher morbidity and mortality associated with COVID-19 among PWH and SOT.